[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100654173":3},{"organization":4,"outcomesModule":7,"designInfo":37,"detailedDescription":43,"studyPopulation":36,"armGroups":44,"interventions":57,"overallOfficials":68,"centralContacts":73,"locations":36,"responsibleParty":79,"collaborators":36,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":36,"eligibilityCriteria":89,"healthyVolunteers":85,"sex":90,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":36,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":104,"overallStatus":109,"whyStopped":36,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":115,"leadSponsor":117,"locationsCount":36},{"fullName":5,"class":6},"Assiut University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":36},[9,13],{"measure":10,"description":11,"timeFrame":12},"Change in platelet count","Change in platelet count (×10⁹\u002FL) from baseline to 12 weeks, comparing the Mediterranean diet intervention group with the control group. Platelet count will be measured by automated hematology analyzer and confirmed by peripheral blood film.","Baseline and 12 weeks",{"measure":14,"description":15,"timeFrame":12},"Change in bleeding severity score","Change in bleeding severity assessed by the ITP-BAT or WHO Bleeding Scale from baseline to 12 weeks. Higher scores indicate more severe bleeding",[17,21,24,27,30,33],{"measure":18,"description":19,"timeFrame":20},"Need for rescue therapy","Proportion of patients requiring rescue therapy (corticosteroids or intravenous immunoglobulin) during the 12-week study period.","12 weeks",{"measure":22,"description":23,"timeFrame":12},"Change in body mass index (BMI)","Change in body mass index (BMI) in kg\u002Fm² from baseline to 12 weeks.",{"measure":25,"description":26,"timeFrame":20},"Incidence and severity of gastrointestinal adverse events related to the Mediterranean diet","Frequency and severity of gastrointestinal side effects and overall tolerability of the selective Mediterranean diet regimen, assessed by patient-reported symptoms.",{"measure":28,"description":29,"timeFrame":12},"Change in Fasting Blood Glucose","Change in fasting blood glucose levels in mg\u002FdL from baseline to 12 weeks.",{"measure":31,"description":32,"timeFrame":12},"Change in Glycated Hemoglobin (HbA1c)","Change in HbA1c percentage (%) from baseline to 12 weeks.",{"measure":34,"description":35,"timeFrame":12},"Change in Lipid Profile","Change in lipid profile parameters (serum total cholesterol, triglycerides, HDL, and LDL) in mg\u002FdL from",null,{"allocation":38,"interventionModel":39,"interventionModelDescription":36,"primaryPurpose":40,"observationalModel":36,"timePerspective":36,"maskingInfo":41},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":42,"maskingDescription":36,"whoMasked":36},"NONE","Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by immune-mediated platelet destruction and impaired platelet production. Emerging evidence suggests that dietary patterns, particularly the Mediterranean diet, may influence immune regulation, systemic inflammation, and gut microbiota, which could affect the course of autoimmune diseases including ITP.\n\nThis randomized controlled trial will assess the effect of a selective Mediterranean diet-based regimen as an adjunct to standard pharmacological treatment on clinical and hematological outcomes in patients with primary ITP. Participants will continue their usual ITP medications throughout the study. The primary focus will be on changes in platelet count and bleeding severity over 12 weeks.",[45,52],{"label":46,"type":47,"description":48,"interventionNames":49},"Mediterranean Diet + Standard Therapy","EXPERIMENTAL","Participants will follow a selective Mediterranean diet regimen in addition to their usual standard treatment for immune thrombocytopenia.",[50,51],"Behavioral: Selective Mediterranean Diet","Drug: Standard Pharmacological Therapy for ITP",{"label":53,"type":54,"description":55,"interventionNames":56},"Standard Therapy Only","ACTIVE_COMPARATOR","Participants will continue their usual standard pharmacological treatment for immune thrombocytopenia without dietary intervention.",[51],[58,63],{"type":59,"name":60,"description":61,"armGroupLabels":62,"otherNames":36},"BEHAVIORAL","Selective Mediterranean Diet","A selective Mediterranean diet regimen based on Mediterranean diet principles with stepwise elimination and reintroduction of certain foods, as an adjunct to standard pharmacological treatment for immune thrombocytopenia (ITP).",[46],{"type":64,"name":65,"description":66,"armGroupLabels":67,"otherNames":36},"DRUG","Standard Pharmacological Therapy for ITP","Standard pharmacological treatment for primary immune thrombocytopenia as prescribed by the treating physician, including corticosteroids (e.g., dexamethasone, prednisone) or intravenous immunoglobulin (IVIg), according to standard clinical guidelines.",[46,53],[69],{"name":70,"affiliation":71,"role":72},"Ahmad F thabet, prof","Internal Medicine Department, Assiut University Hospitals","STUDY_CHAIR",[74],{"name":75,"role":76,"phone":77,"phoneExt":36,"email":78},"Yara G Mekhemer, Resident","CONTACT","01011923969","yara.18313231@med.aun.edu.eg",{"type":80,"investigatorFullName":81,"investigatorTitle":82,"investigatorAffiliation":5,"oldNameTitle":36,"oldOrganization":36},"PRINCIPAL_INVESTIGATOR","Yara Gamal Mekhemer omar","Resident Physician, Department of Internal Medicine","100654173","selective-mediterranean-diet-in-immune-thrombocytopenia-100654173",false,"NCT07798050","Selective Mediterranean Diet in Immune Thrombocytopenia","The Effect of a Selective Mediterranean Diet Regimen on Platelet Count and Clinical Outcomes in Patients With Primary Immune Thrombocytopenia: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18-60 years\n* Diagnosis of primary immune thrombocytopenia according to American Society of Hematology (ASH) criteria\n* Platelet count \\\u003C 100 × 10⁹\u002FL at enrollment\n* Willingness to comply with the dietary protocol and follow-up schedule\n\nExclusion Criteria:\n\n* Secondary thrombocytopenia\n* Pregnancy or lactation\n* Uncontrolled diabetes mellitus, chronic kidney disease, or hepatic failure\n* Strict dietary regimens for other medical conditions\n* History of bariatric surgery or malabsorption syndromes\n* Known food allergies to core Mediterranean diet components\n* Active chemotherapy or splenectomy within the last 3 months\n* Prednisone\u002Fprednisolone ≥ 20 mg\u002Fday (or equivalent) at enrollment or recent dose adjustment within 2 weeks\n* Poor compliance or inability to attend follow-up visits","ALL","18 Years","60 Years",{"count":94,"type":95},60,"ESTIMATED","INTERVENTIONAL",[98],"NA","This randomized controlled trial aims to evaluate the effect of a selective Mediterranean diet regimen, used as an adjunct to standard therapy, on platelet count and bleeding-related outcomes in adult patients with primary immune thrombocytopenia (ITP).",[101,102,103],"Immune Thrombocytopenia","Idiopathic Thrombocytopenic Purpura","Thrombocytopenia",[105,106,107,108],"Mediterranean diet","Immune thrombocytopenia","ITP","Platelet count","NOT_YET_RECRUITING","2026-09-01",{"date":112,"type":113},"2026-09-03","ACTUAL",{"date":110,"type":95},{"date":116,"type":95},"2028-03-25",{"name":5,"class":6}]